Simplify Logo
GE Healthcare

GE Healthcare

Imaging, monitoring, and healthcare IT solutions

Regulatory Affairs Manager - Global Labeling, PDx

Full-TimePosted on 8/10/2026Deadline 9/14/26
$89.6k - $134.4k/yr

+ Performance-based incentive compensation + Cash bonus(es) + Long-term incentives

Senior
Bachelor's
Remote in USA
Remote
No H1B Sponsorship

About the job

Requirements
  • At least 7 years of Regulatory Affairs experience, including significant experience in labeling.
  • Strong knowledge of United States Food and Drug Administration labeling requirements and experience supporting United States regulatory submissions.
  • Experience developing and maintaining United States labeling and/or Core Company Data Sheet.
  • Ability to influence cross-functional teams and manage complex projects.
  • Excellent written and verbal communication skills.
  • The position requires legal authorization to work in the United States.
  • Individuals requiring employment visa sponsorship are not eligible for sponsorship for this opening.
Responsibilities
  • Lead global labeling strategy for assigned products, with primary focus on United States Food and Drug Administration requirements and labeling expectations.
  • Provide labeling input to development programs, lifecycle management activities, and regulatory submissions.
  • Ensure alignment between United States labeling, Core Company Data Sheet, and regional implementation strategies.
  • Lead preparation and review of United States labeling content, including United States Prescribing Information and Food and Drug Administration labeling updates.
  • Support Food and Drug Administration interactions and labeling negotiations.
  • Assess regulatory risks and communicate the impact of Food and Drug Administration feedback on development and commercialization plans.
  • Partner with Clinical, Chemistry, Manufacturing, and Controls, Safety, Medical, Market Access, Commercial, Legal, and Advertising and Promotional teams to develop clear and defensible labeling positions.
  • Translate complex regulatory requirements into business-relevant recommendations.
  • Support labeling governance processes and ensure inspection-ready documentation.
  • Drive timely implementation of labeling changes and continuous process improvement.
  • Contribute to labeling metrics, systems, and best practices across the organization.
  • Support Core Company Data Sheet creation, maintenance, version control, and change-control activities, ensuring United States labeling decisions are assessed for global impact and reflected in global labeling governance.
  • Coordinate with global regulatory leads and regional Regulatory Affairs teams to evaluate local implementation requirements, document deviations or exceptions from the Core Company Data Sheet, and maintain rationale for regional differences.
  • Track implementation of labeling changes across United States and global markets, including milestones, dependencies, approvals, exceptions, and closure status.
  • Maintain labeling trackers, action logs, decision records, and implementation status to support global visibility and inspection readiness.
Desired Qualifications
  • Experience interacting with the Food and Drug Administration on labeling matters.
  • Knowledge of European Union and global labeling requirements.
  • Experience with Veeva Regulatory Information Management or similar regulatory systems.
  • A degree in Life Sciences, Pharmacy, or a related field.

About the company

GE Healthcare Systems provides medical technologies and digital infrastructure to improve diagnosis, treatment, and monitoring of patients. Its products include imaging systems, mobile diagnostic devices, patient monitoring tools, and healthcare IT software that work together as hardware, software, and services to support hospitals, clinics, and researchers. The company differentiates itself with a large, integrated ecosystem, strong focus on AI analytics, and a global service network backed by substantial R&D investment. Its goal is to improve patient outcomes and the efficiency of healthcare delivery by enabling accurate diagnoses, effective treatments, and scaled operations.

Company Size

1-10

Company Stage

IPO

Headquarters

Chicago, Illinois

Founded

1892

Get referred to GE Healthcare

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Photonova Spectra won CE Mark on August 31, 2026, opening Europe sales.
  • Q2 2026 orders rose 11.1%, with 1.15x book-to-bill and record backlog.
  • Vivid cardiovascular ultrasound and ABUS breast screening launches broaden 2026 revenue opportunities.

What critics are saying

  • Patient Care Solutions revenue fell 13.5% in Q2 2026; management is reviewing a sale.
  • Jay Saccaro left in August 2026; William Grogan starts September 14, 2026.
  • If PCS recovery slips into 2027, GE HealthCare becomes a slower-growth imaging vendor.

What makes GE Healthcare unique

  • Photonova Spectra’s Deep Silicon CT differentiates GE HealthCare with photon-counting imaging.
  • GE HealthCare spans imaging, pharma diagnostics, ultrasound, and monitoring across hospital workflows.
  • The July 2026 backlog of $23.9 billion reflects sticky installed-base demand and services.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Tuition Reimbursement

Relocation Assistance

Company News

Yahoo Finance
Sep 1st, 2026
GE HealthCare secures CE mark for Photonova Spectra photon-counting CT system

GE HealthCare has received CE mark approval for its Photonova Spectra photon-counting computed tomography system, enabling commercial sales in markets recognising CE marking. The clearance follows US Food and Drug Administration approval and Japanese regulatory clearance in March 2026. The system uses GE HealthCare's Deep Silicon detector technology to deliver ultra-high definition spectral and spatial imaging. It processes data volumes up to 50 times greater than conventional CT systems, utilising Nvidia's accelerated computing platform. Clinical collaborations are underway at UZ Brussel in Belgium and Rigshospitalet in Denmark to evaluate the system across cardiology, neurology, oncology and musculoskeletal imaging. The CE mark follows more than $5 billion in innovation investment by GE HealthCare.

Yahoo Finance
Aug 31st, 2026
Vertex Pharmaceuticals shows promise while GE HealthCare and Wells Fargo face challenges

Vertex Pharmaceuticals has emerged as a standout S&P 500 stock, according to StockStory's analysis. The company, which focuses on developing transformative medicines for serious diseases including cystic fibrosis and sickle cell disease, boasts a market capitalisation of $137.3 billion. Meanwhile, StockStory recommends avoiding two large-cap stocks. GE HealthCare, spun off from General Electric in 2023, faces concerns over stagnant organic revenue growth and declining operating margins. The medical equipment provider has a market cap of $32.4 billion. Wells Fargo also made the avoid list. The diversified financial services company, with a $262.2 billion market cap, has seen its net interest margin shrink by 33.6 basis points over two years, suggesting increased competition or declining loan profitability.

Associated Press
Aug 28th, 2026
GE HealthCare launches three new Vivid cardiovascular ultrasound systems for diverse care settings

GE HealthCare has introduced three new cardiovascular ultrasound systems to its Vivid portfolio: Vivid Explorer 1, Vivid Advanced 1, and Vivid Focus 1. The systems were unveiled at the European Society of Cardiology Congress 2026 in Munich, Germany. Each system targets different clinical settings whilst sharing a common technology foundation with the ultra-premium Vivid Pioneer. Vivid Explorer is designed for high-volume echo labs, Vivid Advanced for mid-size hospitals and cardiology practices, and Vivid Focus for everyday cardiac imaging. All three systems use cSound imaging technology and include AI-enabled automation tools to streamline echo workflows. The systems have received CE Mark approval but are awaiting US FDA 510(k) clearance and are not yet available for sale in the United States.

Yahoo Finance
Aug 3rd, 2026
GE HealthCare launches Invenia ABUS Prime and StreamVue for breast cancer screening

GE HealthCare has launched Invenia ABUS Prime and ABUS StreamVue, expanding its breast imaging portfolio with solutions for supplemental screening in women with dense breasts. The Invenia ABUS Prime system has been installed at BeSound in Los Angeles, marking one of the first US installations. ABUS StreamVue is a browser-based reading solution enabling remote exam review across imaging networks. The system received FDA 510(k) clearance and CE Marking. Studies show 40% of women have dense breasts, carrying four to six times higher breast cancer risk. Research indicates mammography may miss one-third of cancers in dense breasts. Invenia ABUS Prime features AI-enabled tools including Scan Quality Assessment and can increase scan speed by up to 40%. The AI Assistant has demonstrated a 33% reduction in reading time.

Yahoo Finance
Jul 29th, 2026
GE HealthCare Q2: Orders up 11%, backlog hits record $23.9B amid Patient Care struggles

GE HealthCare Technologies reported second-quarter results with orders rising 11% year-over-year and backlog reaching a record $23.9 billion. Revenue grew 3.5% organically to $5.3 billion, driven by Advanced Imaging Solutions and Pharmaceutical Diagnostics, which posted organic growth of 5% and 14.6% respectively. Patient Care Solutions remained weak, with revenue falling 13.5% due to component shortages and fulfilment problems. Management is reviewing strategic options for the segment, including a potential sale. The company maintained its full-year outlook of 3–4% organic sales growth, adjusted earnings per share of $4.80–$5.00, and approximately $1.6 billion in free cash flow. CFO Jay Saccaro is departing, with George Newcomb serving as interim CFO.

INACTIVE